In specialty and comparator sourcing, the working assumption is that the molecule is the hard part. For restricted-access products, that’s often fair. To secure an authentic, compliant supply is genuinely difficult. But there’s a quieter failure point that sits downstream of procurement: whether the product that arrives can actually be administered.
Fintepla (fenfluramine) oral solution is a clean example of why that distinction matters.
What Fintepla is
Fintepla is an oral solution indicated for seizures associated with Dravet syndrome (DS) and Lennox-Gastaut syndrome (LGS) in patients 2 years of age and older. It carries a boxed warning for valvular heart disease and pulmonary arterial hypertension, and in the US, it is available only through a restricted program under a REMS (the FINTEPLA REMS), which requires cardiac monitoring via echocardiogram before, during, and after treatment.
Those factors alone make it a demanding sourcing target. The less obvious challenge is the ancillaries.
A Regulatory Note Worth Flagging
Because outdated classifications still circulate in sourcing conversations: fenfluramine was originally a Schedule IV controlled substance, but the DEA removed it from control under a final rule that took effect in 2023. It is no longer a federally controlled substance.
The REMS program, however, remains in effect. Descheduling and REMS are two separate things; losing the controlled-substance status did not lift the restricted-distribution or cardiac-monitoring requirements.
The Detail Most Checklists Miss
Fintepla cannot be accurately dosed straight from the bottle. Administration depends on two ancillary components: a press-in bottle adaptor and calibrated, reusable oral dosing syringes.
Per the FDA-approved labeling, in the US, the pharmacist inserts the press-in adaptor into the bottle before dispensing and provides calibrated 3 mL or 6 mL oral syringes at the point of dispensing. The commercial bottle, on its own, does not include them. The label is also explicit that a household spoon is not an acceptable substitute, as the calibrated device is what delivers an accurate dose.
Why This Reshapes The Sourcing Picture
That single fact changes everything about how the product should be sourced.
A bottle obtained outside the normal US pharmacy-dispensing channel can be genuine, in-date, and compliant on paper — and still arrive without the adaptor and syringes needed to measure a single dose. Complete on the invoice; unusable in the room.
So the question is no longer just “Can we get the product?” The question becomes “Which market presentation carries the correct dosing components, and which leaves them to be added at dispensing?” That is the kind of on-the-ground detail that separates a usable delivery from a stalled one.
The Pattern Generalizes
Fintepla is one product, but it illustrates a rule that runs across restricted-access categories — REMS/ETASU products, biologics, orphan drugs, radiopharmaceuticals, and enteral or device-dependent therapies. In these categories, the ancillaries, the component compatibility, and the market-to-market packaging differences frequently decide whether a sourced product is actually usable.
Tracking those details is a distinct capability from finding the molecule. It’s the layer of market intelligence Spring Bio Solution maintains across hard-to-source and restricted products: not just where a product moves, but what it needs to be administered and how that changes from one market to the next.
When a sourcing question turns on that kind of detail, that’s where we can help.
Disclaimer: All product names, trademarks, and brands are the property of their respective owners. Any references are for informational, market-intelligence, and comparator-sourcing purposes only and do not imply endorsement or affiliation.
